Clinical Trial Details
| Trial ID: | L0863 |
| Source ID: | NCT02672709 |
| Associated Drug: | Apixaban |
| Title: | Apixaban in Hemodialysis |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | End-stage Renal Disease |
| Interventions: | DRUG: apixaban |
| Outcome Measures: | Primary: Apixaban concentration, Examine whether apixaban accumulates after an 8-day administration, Day 8 | Secondary: Apixaban concentration before, during, and after hemodialysis, Apixaban levels to be measured before dialysis, then every hour until the end of dialysis on day 2 and day 9, Before dialysis, then every hour until the end of dialysis on day 2 and day 9|Number of participants with treatment related adverse effects, Short-term treatment related adverse effects: bleeding events, allergic reactions, any other symptom reported by the patient that could be attributed to the drug, Day 1 to 9 |
| Sponsor/Collaborators: | Sponsor: Jewish General Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 7 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: |
| Start Date: | 2016-04 |
| Completion Date: | 2016-08 |
| Results First Posted: | |
| Last Update Posted: | 2016-08-30 |
| Locations: | Jewish General Hospital, Montreal, Canada |
| URL: | https://clinicaltrials.gov/show/NCT02672709 |
